UNIVERSITÀ DEGLI STUDI
DI PERUGIA

Perugia, 13 gennaio 2017

Al Direttore del Dipartimento di Scienze Farmaceutiche
Chiar. ma Prof. Violetta Cecchetti

Dipartimento di Scienze Farmaceutiche
17 GEN. 2017
Prot. N. 2867

Oggetto: Elezione del Coordinatore del Corso di Laurea Magistrale in Chimica e Tecnologia Farmaceutiche

In riferimento al Decreto n. 123/2016 con cui sono state indette le votazioni per l'elezione del Coordinatore del CdLM in CTF, comunico la mia candidatura a ricoprire tale carica.

Sono consapevole che l'incarico per il quale mi sto candidando sarà molto gravoso e di grande responsabilità, anche alla luce delle nuove regole per l'accreditamento dei corsi di studio , ma ho deciso di dare la mia disponibilità perché credo di avere acquisito un bagaglio di conoscenze ed esperienze che mi permetteranno di affrontare in modo sereno il lavoro che mi attende.

Grazie alla fiducia che i precedenti Direttori, Presidi e colleghi hanno riposto nella mia persona, negli ultimi 10 anni mi sono stati assegnati numerosi incarichi. Nell'ambito dei vari dottorati di ricerca ho presieduto la commissione per l'attività didattica dei dottorandi e quella per la valutazione degli elaborati. Sono componente della commissione per l' attribuzione delle borse ERASMUS. Sono stata designata quale delegato per le persone con disabilità e delegato per le attività di orientamento. Sono componente del Consiglio del CLA quale referente per l'area 03 e, soprattutto, a decorrere dal 2011 sono componente del Comitato di coordinamento del CdLM in CTF.

Ho ritenuto opportuno rinunciare ad alcuni incarichi per potermi dedicare in modo prioritario, se il Consiglio acconsentirà, all'attività di coordinamento del Corso di Laurea Magistrale in CTF.

Mi sono laureata in CTF nel lontano marzo 1986, questo Corso di Laurea mi ha dato molto e sono onorata di farne parte. Farò tutto quello che sarà nelle mie possibilità per continuare a valorizzarlo, cercando di ascoltare le esigenze degli studenti e dei colleghi.

Farò pienamente riferimento al lavoro compiuto dal precedente Coordinatore, al quale chiedo sin d'ora la disponibilità a collaborare, impegnandomi a lavorare per migliorare alcune criticità del Corso di Studio.

Un'attenzione particolare sarà rivolta a rendere più proficua l'attività di tutorato e orientamento da parte dei docenti, soprattutto nei confronti delle matricole. Lavorerò per incrementare il coordinamento fra le varie discipline. Inoltre, vorrei proporre una revisione delle modalità di discussione della tesi finale e dell'attribuzione dei punti, di cui tante volte abbiamo discusso.

Consapevole delle difficoltà, ma anche fiduciosa nella fattiva collaborazione del Prof. Ricci e di tutti i componenti del Dipartimento, nonché nel validissimo sostegno della Dott.ssa Nucci, intendo dedicarmi con impegno a questa carica.

DIPARTIMENTO DI SCIENZE FARMACEUTICHE
dsf
DIPARTIMENTO SCIENZE FARMACEUTICHE
Via del Liceo, 1
06123 Perugia
Prof. Oriana Tabarrini
Tel +39 075 585 5139
oriana.tabarrini@unipg.it

UNIVERSITÀ DEGLI STUDI
DI PERUGIA

Auspicando il consenso di tutti coloro che fanno parte del nostro Dipartimento, porgo i miei più cordiali saluti.

Prof. Oriana Tabarrini



DIPARTIMENTO DI SCIENZE FARMACEUTICHE

dsf
DIPARTIMENTO
SCIENZE FARMACEUTICHE

Via del Liceo, 1
06123 Perugia

Prof. Oriana Tabarrini

Tel +39 075 585 5139
oriana.tabarrini@unipg.it

Prof. Oriana Tabarrini

Education & qualifications

2002-present, Associate Professor of Pharmaceutical Chemistry, Department of Pharmaceutical Sciences of the University of Perugia (Italy);
1994-2002: research assistant;
1987-1994: post-graduate researcher with research grants from Pharmaceutical Industries;
1986: Degree in Pharmaceutical Chemistry and Technology, summa cum laude, (University of Perugia).

Teaching activities

From AA 1994-95 to AA2001-2002 Analisi dei Medicinali (CTF, 2+3L CFU)
From AA 2002-2003 to AA 2004-2005 Analisi dei Medicinali (CTF, 2+3L CFU), Chimica Farmaceutica (ISF, 10 CFU)
From AA 2005-2006 to AA 2009-2010 Analisi dei Medicinali (CTF, 2+3L CFU), Chimica Farmaceutica (ISF, 10 CFU), Chimica Farmaceutica Biotecnologica (Biotecnologie Farmaceutiche, 3 CFU)
AA 2010-2011 Analisi dei Medicinali (CTF, 3+3L CFU), Chimica Farmaceutica Biotecnologica (Biotecnologie, 3 CFU)
AA 2011-2012 e 2013-2014 Analisi dei Medicinali (CTF, 3+3L CFU) e Chimica Farmaceutica (Farmacia, 11 CFU
AA 2014-2015 Analisi dei Medicinali (CTF, 3+3L CFU)
AA 2015-2016 Chimica Farmaceutica (CTF, 9 CFU)
AA 2016-2017 Analisi dei Medicinali (Farmacia, 2+3L CFU) e Chimica Farmaceutica (CTF, 9 CFU)

Teaching activities at qualified Foreign Universities

2003 (8 hours): School of Pharmacy Jagellonian University Krakow –PL (LLP-Erasmus Program)
2016 (8 hours): Department of Organic Chemistry, Faculty of Chemistry, Wrocław University of Technology, PL (Erasmus Plus)
2016 (8 hours): Department of Organic Chemistry, Faculty of Pharmacy, University of Santiago de Compostela (Erasmus Plus)

Grants

1. Italian Program for AIDS research **2009-2010**: "Targeting HIV transcription to control infection and to purge post-integrative latency". AIDS 2009 Codice progetto UPR-2009-1301355. Starting date December 2010. Duration: 24 months (PI).
2. Fondazione Cassa Risparmio Perugia, Ricerca Scientifica e Tecnologica **2015** : "Sviluppo di farmaci anti-influenzali che interferiscono con il corretto assemblaggio delle subunità polimerasiche". cod. 2015.0342.021. Starting date 3 June 2015. Duration: 12 months (PI).
3. Fondazione Cassa Risparmio Perugia **2010**: "Sviluppo di nuovi farmaci basati sul metabolismo del triptofano per il trattamento della sclerosi multipla". FCR Codice progetto 2010.011.0408. Starting date March 2011. Duration: 18 months (PI).
4. **2014**. Alexander von Humboldt Foundation. "Targeting HIV-1 Trans-activation responsive RNA by halogenated molecules". Duration: 24 months. (Participant)
5. **Progetto Finalizzato 2009.** Italian Ministry of Health and ISS, "Come contrastare la pandemia influenzale: individuazione di nuovi farmaci efficaci". Starting date: November 2009. Duration: 18 (Participant)
6. **PRIN 2008** - cod. 2008CE75SA_002 - "Progettazione, sintesi e attività biologica di agenti anti-HIV che interagiscono con target virali e cellulari innovativi (IN, HAT, Tat/TAR, CDK9, RNasi H, dimerizzazione dell'RT, DDX3, CXCR4 e CCR5)", Starting date: March 2010. Duration: 24 mesi. (Participant)
7. **PRIN 2006** - cod. 2006030809 -: "Sviluppo di derivati chinolonici e di altri eterocicli azotati come agenti anti-HIV: progettazione, sintesi, studio delle interazioni con nuovi target (IN, RNasi H, Tat/TAR) e modulazioni della farmaco-resistenza (NNRTI)". Duration: 24 mesi. (Participant)

8. **PRIN 2004**" Optimization of anti-HIV quinolone derivatives as inhibitors of Tat-drived transactivation", 2004037792_006. Duration 24 months. (Participant)
9. **PRIN 2002** COFIN 2000 - PRIN 2002 - "Ottimizzazione strutturale di chinoloni anti-HIV" - Prot. 2002038878_004. Duration: 24 months. (Participant)
10. **COFIN 2000** - "Progettazione, sintesi e valutazione biologica di nuovi agenti anti-AIDS" - Prot. MM03262952_005. Duration: 24 months. (Participant)
11. **COFIN 1999** – "New agents for the therapy of AIDS and related diseases: design, synthesis and biological assays"-Prot 9903265257_006(Participant)
12. **COFIN 1997**- "Progettazione, sintesi e valutazione biologica di nuovi farmaci" prot 9703028183_003-Duration 24 months. (Participant)

Fellowships and highlights

- **1987-1994**: annual research grants from Mediolanum Pharmaceutics, Milano (Italy)
- The Article: Massari, S.; et al. A 1,8-Naphthyridone Derivative Targets the HIV-1 Tat-Mediated Transcription and Potently Inhibits the HIV-1 Replication. *J. Med. Chem.* **2010**, *53*, 641-64" was mentioned on Science-business eXchange (BioCentury-Nature), 7.01.2010, vol3/number 1 (page 13).
- The Article: Tabarrini, O.; et al "Studies on anti-HIV transcription inhibitor quinolones: Identification of potent N1-vinyl derivatives" *ChemMedChem* **2010**, *5*, 1880-1892 merited the cover picture of the journal.
- The Article: Corona A.; et al. "Studies on Cycloheptathiophene-3-carboxamide Derivatives as Allosteric HIV-1 Ribonuclease H Inhibitors. *ChemMedChem.* **2016** Mar 16. doi: 10.1002/cmdc.201600015 merited the cover picture of the journal.

Coordination, attendance in committees and official appointments

- **2015-present:** Local Coordinator of Paul Ehrlich European Medicinal Chemistry Ph.D. Network http://www.pehrlichmedchem.eu/members.html
- **2015-present:** member of CLA board (University Language Centre)
- **2014-present**: member of HIV/AIDS Committee
- **2014-present**: member of the board of "Pharmaceutical Sciences" Department, University of Perugia
- **2009-2015:** Delegate of the Faculty of Pharmacy and then Department of Pharmaceutical Sciences for CLA activities.
- **2015-present:** Delegate of the Department of Pharmaceutical Sciences for Students Orientation
- **2009-present**: Delegate of the Faculty of Pharmacy and then Department of Pharmaceutical Sciences for Special Needs and Differently-able students.
- **2014-present**: Teaching staff member of the PhD program in "Pharmaceutical Sciences", University of Perugia.
- **2011-present:** Member of the Steering Committee of the Master Degree course in CTF.
- **2007-2016**: Coordinator of the teaching activities of the International PhD course in Chemistry and Technology of Drugs and "Pharmaceutical Sciences"(University of Perugia)
- **2011-2016**: Coordinator of the Evaluation Committee of the annual reports of PhD students.
- **2011-present**: Member of the commettee for the allocation of part-time students.
- **2010 and 2012:** External member of the Examining Board for PhD defense in Pharmaceutical Sciences, Siena (Italy).
- **2009-present:** Member of the Panel for the evaluation of Erasmus and Erasmus Placement fellowships Dept. Pharmaceutical Sciences (ex Faculty of Pharmacy), University of Perugia.
- **2007-2012** Advisor of the Commettee SCI, section Umbria.
- **2002-2014**: Teaching staff member of the PhD program in "Chemistry and Technology of Drugs, International (Perugia, Vienna e Granada) and National profiles", University of Perugia

Oral presentations

2014. "Exploiting the Anti-HIV 6-Desfluoroquinolones to Design Multiple Ligands". V EWDSy: European Workshop in Drug Synthesis. Maggio 18-23, **2014**, Siena, Italy.

2013."Targeting CDKs to inhibit the HIV-1 Tat-mediated transcription" S28, XXII National Meeting on

Medicinal Chemistry. September 10-13, **2013**, Roma – Italy.

2011. "HIV-1 Tat-mediated transcription as attractive intervention site for small molecules. German Research School for Simulation Sciences GmbH, JÜLICH (GERMANY), October, 17-19, 2011.

2010. "HIV-1 Transcription Inhibitors for an Innovative Chemotherapeutic Intervention. XX National Meeting on Medicinal Chemistry". Padova, Italy, September 12-16, 2010, ML-13.

2007. "Quinolones as Tat-mediated transcription inhibitors. Institut Cochin, Paris, April 2007

2007. "New anti-HIV agents". International Centre for Genetic Engineering and Biotechnology (ICGEB), Trieste, Italy, March, 2007

Congresses organizer committees

2016: XXIV National Meeting in Medicinal Chemistry and the 10th Young Medicinal Chemists Symposium "Nuove Prospettive in Chimica Farmaceutica", which will be held in Perugia, September 2016.

2015: IV workshop of the network of multidisciplinary reserach "SeS Redox and Catalysis" Perugia, 20 e 21 April 2015

2014. III workshop of the network of multidisciplinary reserach "SeS Redox and Catalysis" Perugia, 15-17 September, 2014.

2011: XXX TUMA, Perugia, Italy, June 30-July 1, 2011 (organizer and Scientific Commettes)

Referee activity

She is a **referee** for scientific publications: Journal of Medicinal Chemistry, Bioorganic and Medicinal Chemistry, Bioorganic and Medicinal Chemistry Letters, Current Medicinal Chemistry, European Journal of Medicinal Chemistry, ChemMedChem, Amino Acids, ChemPharmBull, Future Medicinal Chemistry, Chemical Biology and Drug Design, Antiviral Research, Future Medicinal Chemistry, Chemistry Open, Biology, Molecules, Letters of Organic Chemistry.

Editors activities

Editor of the special issue entitled "Acting on Tat-mediated transcription to achieve a long term control of HIV-1 latency", *Current Pharmaceutical Design*", expected data of publication: February 2017. http://benthamscience.com/journals/current-pharmaceutical-design/special-issues/#top

Editor of "The scientific pages of HIV and AIDS" http://thescientificpages.org/page/general-medicine/archive.php?jid=hiv-and-aids

Ability to involve and train young researchers

2015-present: Referent of a RTD A (assistant researcher of type A)

2010-present: Tutor and Supervisor of 4 post-doc fellows (paid with Tabarrini's funds).

2007-present: Tutor and Supervisor of 4 PhD students

2006-present Supervisor of 7 incoming and 8 outgoing Erasmus Students

1990-present Supervisor and co-advisor of more than 80 experimental diploma work thesis

Scientific Publications

bibliographical data at 21/10/2016 (* wos database)

84 publications
4 patents
Total number of citations: 1314 (*)
H-index: 21 (*)

summary of the last 5 years publications (2012-2016)

29 papers
Corresponding author = 13
Senior = 12
Papers in category Q1 = 17

Patents

1. Loregian A, Palù G, Muratore G, Cruciani G, Tabarrini O. New inhibitors of influenza A and B viruses acting by disrupting PA and PB1 subunit interactions of heterotrimeric viral RNA polymerase. WO2013123974-A1, Aug, 29, **2013**.
2. Loregian, A., Palù, G., Mercorelli, B., Tabarrini, O., Cecchetti, V. Compositions and methods for the treatment of the pathological condition(s) associated to cytomegalovirus infection" US provisional Application No 61/374.320 filing date Aug, 17, **2010**.
3. V. Cecchetti, A. Fravolini, O. Tabarrini, P. Terni, T. Xin. Derivati Chinolonici non Fluorurati e Loro Impiego come Agenti Antibatterici. Brev. Italiano MI95A001593, **1996**
4. V. Cecchetti, A. Fravolini, P. Terni, P.G. Pagella, O. Tabarrini. 6-Aminoquinolones, their Synthesis and their Use as Antibacterial Agents. Eur. Pat. Appl. EP 531,958; *Chem. Abstr. 119*, **1993**, 139267.

List of Publications

1. Massari S, Goracci L, Desantis J, **Tabarrini O**. Polymerase Acidic Protein-Basic Protein 1 (PA-PB1) Protein-protein Interaction as a Target for Next-generation Anti-influenza Therapeutics. *J Med Chem*. **2016**, 59, 7699-718.
2. **Tabarrini** O, Desantis J, Massari S. Recent advances in the identification of Tat-mediated transactivation inhibitors: progressing toward a functional cure of HIV. *Future MedChem*. **2016** 8, 421-42.
3. Corona A, Desantis J, Massari S, Distinto S, Masaoka T, Sabatini S, Esposito F, Manfroni G, Maccioni E, Cecchetti V, Pannecouque C, Le Grice SF, Tramontano E, **Tabarrini O.** Studies on Cycloheptathiophene-3-carboxamide Derivatives as Allosteric HIV-1 Ribonuclease H Inhibitors. *ChemMedChem*. **2016**, *11*, 1709-20.
4. Mercorelli B, Luganini A, Nannetti G, **Tabarrini O**, Palù G, Gribaudo G, Loregian A. Drug Repurposing Approach Identifies Inhibitors of the Prototypic Viral Transcription Factor IE2 that Block Human Cytomegalovirus Replication.*Cell Chem Biol*. **2016,** *23*, 340-51.
5. Palomba M, Rossi L, Sancineto L, Tramontano E, Corona A, Bagnoli L, Santi C, Pannecouque C, **Tabarrini O**, Marini F. A new vinyl selenone-based domino approach to spirocyclopropyl oxindoles endowed with anti-HIV RT activity. *Org Biomol Chem*. **2016**, *14*, 2015-24.
6. Sancineto L, Mariotti A, Bagnoli L, Marini F, Desantis J, Iraci N, Santi C, Pannecouque C, **Tabarrini O**. *Design and Synthesis of DiselenoBisBenzamides (DISeBAs) as Nucleocapsid Protein 7 (NCp7) Inhibitors with anti-HIV Activity. J Med Chem*. **2015** *58(24), 9601-14.*
7. A Bochicchio, G Rossetti, O Tabarrini, S Krauβ, P Carloni. Molecular View of Ligands Specificity for CAG Repeats in Anti-Huntington Therapy. *J. Chem. Theory Comput.* **2015** 11, 4911-22.
8. Machado, D, Cannalire, R, Costa, SS, Manfroni, G, **Tabarrini, O**, Cecchetti, V, Couto, I Viveiros, M, Sabatini, S, ACS INFECTIOUS DISEASES. Boosting Effect of 2-Phenylquinoline Efflux Inhibitors in Combination with Macrolides against Mycobacterium smegmatis and Mycobacterium avium, **2015,** *1*, 593-603.
9. Franci G, Manfroni G, Cannalire R, Felicetti T, Tabarrini O, Salvato A, Barreca ML, Altucci L, Cecchetti V. Tumour cell population growth inhibition and cell death induction of functionalized 6-aminoquinolone derivatives. *Cell Prolif.* **2015** 48, 705-17.
10. Massari S, Nannetti G, Desantis J, Muratore G, Sabatini S, Manfroni G, Mercorelli B, Cecchetti V, Palù G, Cruciani G, Loregian A, Goracci L, **Tabarrini O**. A Broad Anti-influenza Hybrid Small Molecule That Potently Disrupts the Interaction of Polymerase Acidic Protein-Basic Protein 1 (PA-PB1) Subunits. *J Med Chem*. 58, 3830-42, **2015.**
11. Sabatini S, Manfroni G, Barreca ML, Bauer SM, Gargaro M, Cannalire R, Astolfi A, Brea J, Vacca C, Pirro M, Massari S, **Tabarrini O**, Loza MI, Fallarino F, Laufer SA, Cecchetti V. The pyrazolobenzothiazine core as a new chemotype of p38 alpha mitogen-activated protein kinase inhibitors. *Chem Biol Drug Des*. **2015** Jan 14. doi: 10.1111/cbdd.12516.
12. Mercorelli B, Luganini A, Muratore G, Massari S, Terlizzi ME, **Tabarrini O**, Gribaudo G, Palù G, Loregian A.The 6-Aminoquinolone WC5 Inhibits Different Functions of the Immediate-Early 2 (IE2) Protein of Human Cytomegalovirus that are Essential for Viral Replication. *Antimicrob Agents Chemother*. **2014**, *58*, 6615-26
13. Sancineto L, Iraci N, Barreca ML, Massari S, Manfroni G, Corazza G, Cecchetti V, Marcello A, Daelemans D, Pannecouque C, **Tabarrini O**. Exploiting the anti-HIV 6-desfluoroquinolones to design multiple ligands. *Bioorg Med Chem*. **2014** Sep 1;22(17):4658-66.
14. Donalisio M, Massari S, Argenziano M, Manfroni G, Cagno V, Civra A, Sabatini S, Cecchetti V, Loregian A, Cavalli R, Lembo D, **Tabarrini O**. Ethyl 1,8-Naphthyridone-3-carboxylates Downregulate Human Papillomavirus-16 E6 and E7 Oncogene Expression. *J. Med. Chem.*, **2014**, *57*, 5649-63.

15. Barreca ML, Iraci N, Manfroni G, Gaetani R, Guercini C, Sabatini S, **Tabarrini O**, Cecchetti V Accounting for Target Flexibility and Water Molecules by Docking to Ensembles of Target Structures: The HCV NS5B Palm Site I Inhibitors Case Study. *J Chem Inf Model.* **2014,** 54, 481-97.
16. Manfroni G, Manvar D, Barreca ML, Kaushik-Basu N, Leyssen P, Paeshuyse J, Cannalire R, Iraci N, Basu A, Chudaev M, Zamperini C, Dreassi E, Sabatini S, **Tabarrini O**, Neyts J, Cecchetti V. New Pyrazolobenzothiazine Derivatives as Hepatitis C Virus NS5B Polymerase Palm Site I Inhibitors. *J Med Chem.* **2014**, *57*, 3247-62.
17. Royle CM, Tsai MH, **Tabarrini O**, Massari S, Graham DR, Aquino VN, Boasso A. Modulation of HIV-1-induced activation of plasmacytoid dendritic cells (pDCs) by 6-desfluoroquinolones. *AIDS Res Hum Retroviruses.* **2014,** *30*, 345-54.
18. Manfroni G, Cannalire R, Barreca ML, Kaushik-Basu N, Leyssen P, Winquist J, Iraci N, Manvar D, Paeshuyse J, Guhamazumder R, Basu A, Sabatini S, **Tabarrini O**, Danielson UH, Neyts J, Cecchetti V. The versatile nature of the 6-aminoquinolone scaffold: identification of submicromolar hepatitis C virus NS5B inhibitors. *J Med Chem.* **2014,** *57*, 1952-1963.
19. Massari S, Nannetti G, Goracci L, Sancineto L, Muratore G, Sabatini S, Manfroni G, Mercorelli B, Cecchetti V, Facchini M, Palù G, Cruciani G, Loregian A, **Tabarrini O**. Structural Investigation of Cycloheptathiophene-3-carboxamide Derivatives Targeting Influenza Virus Polymerase Assembly. *J Med Chem.* **2013**, *56*,10118-31.
20. Sancineto L, Iraci N, Massari S, Attanasio V, Corazza G, Barreca ML, Sabatini S, Manfroni G, Avanzi NR, Cecchetti V, Pannecouque C, Marcello A, **Tabarrini O.** Computer-Aided Design, Synthesis and Validation of 2-Phenylquinazolinone Fragments as CDK9 Inhibitors with Anti-HIV-1 Tat-Mediated Transcription Activity. *ChemMedChem.* **2013**, *8*, 1941-53.
21. Barreca M L, Manfroni G, Leyssen P, Winquist J, Kaushik-Basu N, Paeshuyse J, Krishnan R, Iraci N, Sabatini S, **Tabarrini O**, Basu A, Danielson UH, Neyts J, Cecchetti V Structure-based discovery of pyrazolobenzothiazine derivatives as inhibitors of hepatitis C virus replication. *J Med Chem.* **2013**, 56, 6, 2270-82.
22. Sancineto L, Massari S, Iraci N,**Tabarrini O**. From Small to Powerful: The Fragments Universe and its "Chem-Appeal" *Curr Med Chem.* **2013**, *20*, 1355-81.
23. Martelli A, Manfroni G, Sabbatini P, Barreca ML, Testai L, Novelli M, Sabatini S, Massari S, **Tabarrini O**, Masiello P, Calderone V, Cecchetti V. 1,4-Benzothiazine ATP-sensitive potassium channel openers: modifications at the C-2 and C-6 positions. *J Med Chem.* **2013** 56, 4718-28.
24. Sabatini S, Gosetto F, Iraci N, Barreca ML, Massari S, Sancineto L, Manfroni G, **Tabarrini O**, Dimovska M, Kaatz GW, Cecchetti V Re-evolution of the 2-phenylquinolines: ligand-based design, synthesis, and biological evaluation of a potent new class of Staphylococcus aureus NorA efflux pump inhibitors to combat antimicrobial resistance.. *J Med Chem.* **2013** 56, 4975-89.
25. Massari S, Mercorelli B, Sancineto L, Sabatini S, Cecchetti V, Gribaudo G, Palù G, Pannecouque C, Loregian A, **Tabarrini O**. Design, synthesis, and evaluation of WC5 analogues as inhibitors of human cytomegalovirus Immediate-Early-2 protein, a promising target for anti-HCMV treatment. *ChemMedChem.* **2013,** 8, 1403-14.
26. Massari S, Sabatini S, **Tabarrini O**. Blocking HIV-1 Replication by Targeting the Tat-Hijacked Transcriptional Machinery. *CurrPharmDes.* **2013**, *19*, 1860-1879.
27. Pieroni M; Sabatini S, Massari, S, Kaatz, G , Cecchetti V, **Tabarrini O**. Searching for innovative quinolone-like scaffolds: synthesis and biological evaluation of 2,1-benzothiazine 2,2-dioxide derivatives. *MedChemComm.* **2012**, *3*, 1092-1097.
28. **Tabarrini O**, Sabatini S, Massari S, Pieroni M, Franzblau S.G, Cecchetti V. 6-hydrogen-8-methylquinolones active against replicating and non-replicating Mycobacterium tuberculosis. *Chem Biol Drug Des.* **2012**, 5, 781-6.
29. Sabatini S, Gosetto F, Serritella S, Manfroni G, **Tabarrini O**, Iraci N, Brincat JP, Carosati E, Villarini M, Kaatz GW, Cecchetti V. Pyrazolo[4,3-c][1,2]benzothiazines 5,5-dioxide: a promising new class of Staphylococcus aureus NorA efflux pump inhibitors. *J. Med. Chem.* **2012**; *55*, 3568-72.
30. **Tabarrini**, O.; Massari, S.; Sancineto, L.; Daelemans, D.; Sabatini, S.; Manfroni, G.; Cecchetti, V.; Pannecouque, C. Structural Investigation on naphthyridone scaffold: identification of 1,6-naphthyridone derivative with potent and selective anti-HIV activity. *ChemMedChem.* **2011**, 85, 1392-7.
31. Sabatini S, Gosetto F, Manfroni G, **Tabarrini O**, Kaatz GW, Patel D, Cecchetti. Evolution from a natural flavones nucleus to obtain 2-(4-Propoxyphenyl)quinoline derivatives as potent inhibitors of the S. aureus NorA efflux pump. *J Med Chem.* **2011,** *54,* 5722-36.
32. Natalini, B.; Sardella R.; Massari S.; Ianni F.; **Tabarrini** O.; Cecchetti V. Synthesis and chromatographic enantioresolution of anti-HIV quinolone derivatives **2011**. 6, 1249-57.
33. Manfroni, G.; Meschini, F.; Costantino, F.; **Tabarrini**, O.; Cecchetti, V. *N*-Benzoyl-*N*-methylsulfonylanthranilates: unexpected cyclization reaction to 4-alkoxy-2,1-benzothiazines. *Arkivoc* **2011**, (ix) 165-176.
34. **Tabarrini, O.**; Massari, S.; Daelemans, D.; Meschini, F.; Manfroni, G.; Bottega, L.; Gatto, B.; Palumbo, M.; Pannecouque, C.; Cecchetti, V. Studies on anti-HIV transcription inhibitor quinolones: Identification of potent N1-vinyl derivatives. *ChemMedChem.* **2010**, *5*, 1880-1892.
35. **Tabarrini, O.**; Massari, S.; Cecchetti, V. 6-Desfluoroquinolones As HIV-1 Tat-Mediated Transcription Inhibitors. *Future Med. Chem.* **2010**, *2*, 1161-1180.
36. Loregian, A.; Mercorelli, B.; Muratore, G.; Sinigalia, E.; Pagni, S.; Massari, S.; Gribaudo, G.; Gatto, B.; Palumbo, M.; **Tabarrini, O.**; Cecchetti, V.; Palù, G. The 6-aminoquinolone WC5 inhibits human cytomegalovirus replication at an

early stage by interfering with the transactivating activity of viral immediate-early 2 protein. *Antimicrob. Agents Chemother* **2010,** *54,* 1930-1940.

37. Massari, S.; Daelemans, D.; Barreca, M.L.; Knezevich, A.; Sabatini, S.; Cecchetti, V.; Marcello, A.; Pannecouque, C.; **O. Tabarrini**. A 1,8-Naphthyridone Derivative Targets the HIV-1 Tat-Mediated Transcription and Potently Inhibits the HIV-1 Replication. *J. Med. Chem.* **2010**, *53*, 641-648.
38. Massari, S.; Daelemans, D.; Manfroni, G.; Sabatini, S.; **Tabarrini, O.**; Pannecouque, C.; Cecchetti, V. Studies on Anti-HIV Quinolones: New Insights on the C-6 Position. *Bioorg. Med. Chem.* **2009**, *17*, 667-674.
39. Mercorelli, B.; Muratore, G.; Sinigalia, E.; **Tabarrini, O.**; Biasolo, M.A.; Cecchetti, V.; Palu, G.; Loregian, A. A 6-Aminoquinolone Compound, WC5, with Potent and Selective Anti-Human Cytomegalovirus Activity. *Antimicrob. Agents Chemother* **2009,** *53,* 312-5
40. Manfroni, G.; Gatto, B.; **Tabarrini, O.**; Sabatini, S.; Cecchetti, V.; Giaretta, G.; Parolin, C.; Del Vecchio, C.; Calisti, A.; Palumbo, M.; Fravolini, A. Synthesis and Biological Evaluation of 2-Phenylquinolones Targeted at Tat/TAR Recognition *Bioorg. Med. Chem. Lett.* **2009**, *19*, 714-717.
41. Manfroni, G. Paeshuyse, J., Massari, S., Gatto, B.; Zanoli, S.; Maga, G.; **Tabarrini, O.**; Cecchetti, V.; Fravolini, A. Neyts, J. Inhibition of Subgenomic Hepatitis C Virus RNA Replication by Acridone Derivatives: Identification of an NS3 Helicase Inhibitor. *J. Med. Chem.* **2009**, *52,* 3354-3365.
42. Gatto, B.; **Tabarrini, O.**; Massari, S.; Giaretta, G.; Sabatini, S.; Del Vecchio, C.; Parolin, C.; Fravolini, F.; Palumbo, M.;Cecchetti, V. 2-Phenylquinolones as Inhibitors of the HIV-1 Tat/TAR Interaction. *Chem. Med. Chem.* **2009**, *4,* 935-938
43. Spogli, R.; Sabatini, S.; Manfroni, G.; **Tabarrini O.**; Cecchetti, V. Synthesis of 2-(Arylamino)ethanethiols via Lewis Acid catalyzed Aminolysis of 2,2-Dimethylthiirane as Precursors of the 1,4-Benzothiazine Nucleus. *Synthesis*, **2009**, *9*, 1513-1519.
44. Calderone, V.; Spogli, R.; Martelli, A.; Manfroni, G. Testai, L.; Sabatini, S.; **Tabarrini, O.**; Cecchetti, V. Novel 1,4-Benzothiazine Derivatives as Large Conductance Ca $^{2+}$-Activated Potassium Channel Openers. *J. Med. Chem.* **2008**, *51*, 5085-5092.
45. **Tabarrini, O.**; Massari, S.; Daelemans, D.; Stevens, M.; Manfroni, G.; Sabatini, S.; Balzarini, J.; Cecchetti, V.; Pannecouque, C.; Fravolini, A. Structure-Activity Relationship Study on Anti-HIV 6-Desfluoroquinolones. *J. Med. Chem.* **2008**, *51*, 5454-5458.
46. Paeshuyse, J.; Inge Vliegen, I.; Coelmont, L.; Leyssen, P.; **Tabarrini, O.**; Herdewijn, P.; Mittendorfer, H.; Easmon, J.; Cecchetti, V.; Bartenschlager, R.; Puerstinger, G.; Neyts, J. Comparative in vitro anti-hepatitis C virus activities of a selected series of polymerase, protease, and helicase inhibitors. *Antimicrob Agents Chemother.* **2008**, *52*, 3433-3337.
47. Stevens, M.; Pollicita, M.; Pannecouque, C.; Verbeken, E.; **Tabarrini, O.**; Cecchetti, V.; Acquaro, S.; Perno, C. F.; Fravolini, A.; Schols, D.; De Clercq, E; Balzarini, J. A Novel *in vivo* Model for the Study of HIV-1 Transcription Inhibitors: Evaluation of New 6-Desfluoroquinolone Derivatives (6-DFQs). *Antimicrob. Agents. Chemother.* **2007**, *4*, 1407-1413.
48. Cecchetti, V.; **Tabarrini,** O.; Sabatini, S. From cromakalim to different structural classes of K_{ATP} channel openers. *Curr. Top. Med. Chem.* **2006**, *6*, 1049-1068.
49. **Tabarrini, O.**; Manfroni, G.; Fravolini, A.; Cecchetti, V.; Sabatini, S.; De Clercq, E.; Rozenski, J.; Canard, B.; Dutartre, H.; Paeshuyse, J.; Neyts, J. Synthesis and anti-BVDV activity of acridones as new potential antiviral agents. *J. Med. Chem.* **2006**, *49*, 2621-2627.
50. Dirk, D.; Pannecouque, C.; Pavlakis, G. N.; **Tabarrini, O.**; De Clercq, E. A novel and efficient approach to discriminate between pre- and post-transcription HIV inhibitors. *Mol. Pharmacol.* **2005**, *67*, 1574-1580.
51. Minelli, A.; Bellezza, I.; Siciliano, E.; Liguori, L.; **Tabarrini, O.**; Cecchetti, V.; Fravolini, A. Inhibition od cell growth and induction of apoptosis in human prostate cancer cell lines by 6-aminoquinolone WM13. *Oncology Report.* **2005**, *13*, 1113-1120.
52. Carosati, E.; Lemoine, H.; Spogli, R.; Grittner, D.; Mannhold, R.; **Tabarrini, O.**; Sabatini, S.; Cecchetti, V. Binding studies and GRIND/ALMOND-based 3D QSAR analysis of benzothiazine type K_{ATP}-channel openers. *Bioorg. Med. Chem.* **2005**, *13*, 5581-5591.
53. Stevens, M.; Balzarini, J.; **Tabarrini, O.**; Andrei, G.; Snoeck, R.; Cecchetti, V.; Fravolini A.; De Clercq, E.; Pannecouque, C. Cell-dependent interference of a series of new 6-aminoquinolone derivatives with viral (HIV/CMV) transactivation. *J. Antimicrob. Chemother.* **2005**, *56,* 847-855.
54. Richter, S.; Gatto, B.; **Tabarrini, O.**; Fravolini, A.; Palumbo, M. Antiviral 6-aminoquinolones: Molecolar basis for potency and selectivity. *Bioorg. Med. Chem. Lett.* **2005**, *15*, 4247-4251.
55. Stevens, M; Tabarrini, O; Cecchetti, V; De Clercq E, Fravolini A, Pannecouque C. Cell-dependent interference with viral transactivation by 6-aminoquinolone derivatives *Antivir. Res* 65, Pages:A55-A55 Mar. **2005.**
56. **Tabarrini, O.**; Stevens, M.; Cecchetti, V.; Sabatini, S.; Dell'uomo, M.; Manfroni, G.; Palumbo, M.; Pannecouque, C.; De Clercq, E.; Fravolini, A. Structure modifications of 6-aminoquinolones with potent anti-HIV activity. *J Med Chem.*, **2004**, *47*, 5567-5578.
57. Viola G, Facciolo L, Dall'Acqua S, Di Lisa F, Canton M, Vedaldi D, Fravolini A, **Tabarrini O**, Cecchetti V. 6-Aminoquinolones: Photostability, Cellular Distribution and Phototoxicity. *Toxicol in Vitro*, **2004**, *18*, 581-592.

58. Cecchetti, V.; Calderone, V.; **Tabarrini, O.**; Sabatini, S.; Filipponi, E.; Testai, L.; Spogli, R.; Martinotti, E.; Fravolini. A.; Highly Potent 1,4-Benzothiazine Derivatives as K_{ATP}-Channel Openers. *J. Med. Chem.* **2003**, *46*, 3670-3679.
59. G. Miolo, D. Vedaldi; F. Dall'Acqua; A. Fravolini; **O.Tabarrini**; V. Cecchetti. In vitro phototoxic properties of new 6-desfluoro-8-methylquinolones. *Toxicology in Vitro*. **2002**, *16*, 683-693.
60. Filipponi, E.; Cruciani, G.; **Tabarrini, O.;** Cecchetti, V.; Fravolini, A. 3D-QSAR study of anti-HIV quinolone library. *J. Comp. Aid. Mol. Des.*, **2001**, *15*, 203-217.
61. **O. Tabarrini**, V. Cecchetti, A. Temperini, E: Filipponi, M. G. Lamperti, A. Fravolini. Velnacrine Thiaanalogues as Potential Agents for Treating Alzheimer's Disease. *Bioorg. &. Med. Chem.* **2001**, *9*, 2921-2928.
62. E. Filipponi, V. Cecchetti, **O. Tabarrini**, D. Bonelli, A. Fravolini. Chemometric Rationalization of the Structural and Physicochemical Basis for Selective Cyclooxygenase-2 Inhibition: Toward More Specific Ligands. *J. Comp. Aid. Mol. Des.* **2000**, *14*, 277-291.
63. V. Cecchetti, F. Schiaffella, **Tabarrini, O.**, A. Fravolini. (1,4-Benzothiazinyloxy)alkylpiperazine Derivatives as Potential Antihypertensive Agents. *Bioorg. &. Med. Chem. Lett.* **2000**, *10*, 465-468.
64. M. Hua, V. Cecchetti, **O. Tabarrini**, A. Fravolini. New 1,8-peri-Annellated Tricyclic Quinolone Antibacterials. *J. Heterocyclic Chem.* **2000**, *37*, 297-301.
65. V. Cecchetti, C. Parolin, S. Moro, T. Pecere, E. Filipponi, A. Callistri, **O. Tabarrini**, B. Gatto, M.Palumbo, A. Fravolini, G. Palù. 6-Aminoquinolones as New Potential Anti-HIV Agents. *J. Med. Chem.* **2000**, *43*, 3799-3802.
66. **O.Tabarrini**, C. Sissi, A. Fravolini, M. Palumbo. 6-Hydroxy Derivative as New Desfluoroquinlone (DFQ): Synthesis and DNA-binding Study. *Nucleosides, Nucleotides and Nucleic Acids*, **2000**, *19*, 1327-1336.
67. **O. Tabarrini**, V. Cecchetti, A. Fravolini, G. Nocentini, A. Barzi, S. Sabatini, H. Miao, C. Sissi. Design and Synthesis of Modified Quinolones as Antitumoral Acridones. *J. Med. Chem.* **1999**, *42*, 2136-2144.
68. De Sarro, V. Cecchetti, A. Fravolini, **O. Tabarrini**, F. Naccari, G. De Sarro. Effects of Novel 6-Desfluoroquinolones on Pentylentetrazole-induced Seizures in Mice. *Antimicrob. Agents Chemother.* **1999**, *43*, 1729-1736.
69. S. Sabatini, V. Cecchetti, **O. Tabarrini**, A. Fravolini. 8-Methyl-7-substituted-1,6-naphthyridine-3-carboxylic Acids as New 6-Desfluoroquinolone Antibacterials. *J. Heterocyclic Chem.* **1999**, *36*, 953-957.
70. V. Cecchetti, **O. Tabarrini**, S. Sabatini, H. Miao, E. Filipponi, A. Fravolini. Studies on 6-Aminoquinolones: Synthesis and Antibacterial Evaluation of 6-Amino-8-ethyl- and 6-Amino-8-methoxyquinolones. *Bioorg. &. Med. Chem.* **1999**, *7*, 2465-2471.
71. V. Cecchetti, A. Fravolini, S. Sabatini, **O. Tabarrini**, T. Xin. Dibenzo[1,6]naphthyridinediones as Modified Quinolone Antibacterials. *Eur. J. Med. Chem.* **1998**, *33*, 899-903.
72. V. Cecchetti, E. Filipponi, A. Fravolini, **O. Tabarrini**, D. Bonelli, M. Clementi, G. Cruciani, S. Clementi. Chemometric Methodologies in a Quantitative Structure-Activity Relationship Study: the Antibacterial Activity of 6-Aminoquinolones. *J. Med. Chem.* **1997**, *40*, 1698-1706.
73. V. Cecchetti, G. Cruciani, E. Filipponi, A. Fravolini, **O. Tabarrini**, T. Xin. Synthesis and Antibacterial Evaluation of [1,3]Benzothiazino[3,2-*a*]quinoline and [3,1]Benzothiazino[1,2-*a*]quinoline-6-carboxylic Acid Derivatives. *Bioorg. &. Med. Chem.* **1997**, *5*, 1339-1344.
74. M. Carbone, M.T. Fera, V. Cecchetti, **O. Tabarrini**, E. Losi, V. Cusumano, G. Teti. In Vitro Activities of New Quinolones Against *Helicobacter pylori. Antimicrob. Agents Chemother.* **1997**, *41*, 2790-2792.
75. V. Cecchetti, A. Fravolini, M.C. Lorenzini, **O. Tabarrini**, P. Terni, T. Xin. Studies on 6-Aminoquinolones: Synthesis and Antibacterial Evaluation of 6-Amino-8-methylquinolones. *J. Med. Chem.* **1996**, *39*, 436-445.
76. V. Cecchetti, A. Fravolini, M. Palumbo, C. Sissi, **O. Tabarrini**, P. Terni, T. Xin. Potent 6-Desfluoro-8-methylquinolones as New Lead Compounds in Antibacterial Chemotherapy. *J. Med. Chem.* **1996**, *39*, 4952 4957.
77. V. Cecchetti, S. Clementi, G. Cruciani, A. Fravolini, P.G. Pagella, A. Savino, **O. Tabarrini**. 6-Aminoquinolones: A New Class of Quinolone Antibacterials? *J. Med. Chem.* **1995**, *38*, 973-982.
78. R. Wise, P.G. Pagella, V. Cecchetti, A. Fravolini, **O. Tabarrini**. *In Vitro* Activity of MF 5137, a New Potent 6-aminoquinolone. *Drugs* **1995**, *49*, 272-273.
79. V. Cecchetti, A. Fravolini, P.G. Pagella, **O. Tabarrini**, A. Temperini. 7-(Disubstituted Thiazolyl)-3,5-dihydroxy-6-Heptenoic/Hepatanoic Acid Derivatives as HMG-CoA Reductase Inhibitors. *Bioorg. &. Med. Chem.* **1994**, *2*, 799-806.
80. V. Cecchetti, A. Fravolini, F. Schiaffella, **O. Tabarrini**, G. Bruni, G. Segre. *o*-Chlorobenzenesulfonamidic Derivatives of (Aryloxy)propanolamines as β-Blocking/Diuretic Agents. *J. Med. Chem.* **1993**, *36*, 157-161.
81. V. Cecchetti, A. Fravolini, P.G. Pagella, A. Savino, **O. Tabarrini**. Quinoline Carboxylic Acids. 3. Synthesis and Antibacterial Evaluation of 2- Subsituted-7-oxo-2,3-dihydro-7*H*-pyrido[1,2,3-*de*][1,4]benzothiazine-6-carboxylic Acids Related to Rufloxacin. *J. Med. Chem.* **1993**, *36*, 3449-3454.
82. V. Cecchetti, A. Fravolini, R. Fringuelli, F. Schiaffella, M.C. Lorenzini, **O. Tabarrini**. 4*H*-1,4-Benzothiopyran-4-one-3-carboxylic Acids and 3,4-Dihydro-2*H*-isothiazolo[5,4-*b*][1]benzothiopyran-3,4-diones as Quinolone Antibacterial Analogs. *J. Heterocyclic Chem.* **1993**, *30*, 1143-1148.
83. V. Cecchetti, A. Fravolini, P.G. Pagella, **O. Tabarrini**, W. Zhou. 1,4-Benzothiazine-2-carboxylic Acids 1-Oxide as Analogue of Antibacterial Quinolones. *J. Heterocyclic Chem.* **1992**, *29*, 375-382.

84. V. Cecchetti, F. Schiaffella, **O. Tabarrini**, W. Zhou, A. Fravolini, A. Goi, G. Bruni, G. Segre. Symbiotic Approach to Drug Design: *N*-[(4-Chloro-3-sulfamoylbenzamido)-ethyl]propanolamine Derivatives as β-Adrenergic Blocking Agents with Diuretic Activity. *Eur. J. Med. Chem.* **1991**, *26*, 381-386.